m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05125
 [1]
Non-coding RNA CircCELF1 FTO  lncRNA       miRNA   circRNA Direct Enhancement m6A modification DKK2 DKK2 FTO Demethylation : m6A sites
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target Dickkopf-related protein 2 (DKK2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_CELF1 circRNA View Details
Regulated Target FTO alpha-ketoglutarate dependent dioxygenase (FTO) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary Ang II induced downregulation of Circ_CELF1 expression, while circCELF1 enhanced the expression of Dickkopf-related protein 2 (DKK2) by adsorbing miR-636. circCELF1 also reduced DKK2 m6A level by upregulating FTO expression, thereby inhibiting the binding of miR-636 to DKK2 and promoting DKK2 expression.
Responsed Disease Myocardial Fibrosis ICD-11: BC43.20
 Disease Info 
In-vivo Model The AMI model was induced by permanent ligation of the left coronary artery anterior descending with a 7-0 surgical suture as previously described , and then miR-636 antagomir (10 mg/kg; RiboBio) was injected through the tail vein of mice or the nanoparticles with DKK2 plasmids were administered intraperitoneally in a volume of 200 μ L into AMI mice.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
BC43: Cardiomyopathy 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Levosimendan Approved [2]
Synonyms
Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
    Click to Show/Hide
External Link
CID: 3033825
TTD: D0C4HG
DrugBank: DB00922
 Compound Name ALN-TTRsc Phase 3 [3]
Synonyms
SAR438714
    Click to Show/Hide
External Link
TTD: D0E9AF
 Compound Name PB1046 Phase 1 [4]
Synonyms
Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
    Click to Show/Hide
External Link
TTD: D0G9JQ
References
Ref 1 circCELF1 Inhibits Myocardial Fibrosis by Regulating the Expression of DKK2 Through FTO/m(6)A and miR-636. J Cardiovasc Transl Res. 2022 Oct;15(5):998-1009. doi: 10.1007/s12265-022-10209-0. Epub 2022 Feb 7.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT02319005) ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). U.S. National Institutes of Health.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)